Universal Beteiligungs und Servicegesellschaft mbH Acquires 15,217 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 9.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,543 shares of the company’s stock after purchasing an additional 15,217 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.29% of Harmony Biosciences worth $5,326,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in HRMY. Mirae Asset Global Investments Co. Ltd. increased its stake in Harmony Biosciences by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock worth $70,000 after buying an additional 299 shares during the period. Gallacher Capital Management LLC boosted its position in Harmony Biosciences by 4.3% in the 2nd quarter. Gallacher Capital Management LLC now owns 9,981 shares of the company’s stock valued at $315,000 after buying an additional 413 shares during the period. Rhumbline Advisers grew its stake in Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock worth $3,620,000 after acquiring an additional 485 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of Harmony Biosciences by 1.6% during the second quarter. New York State Teachers Retirement System now owns 32,293 shares of the company’s stock worth $1,020,000 after acquiring an additional 500 shares during the period. Finally, CWM LLC increased its position in shares of Harmony Biosciences by 34.8% during the first quarter. CWM LLC now owns 2,704 shares of the company’s stock worth $90,000 after acquiring an additional 698 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Needham & Company LLC lowered their price target on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, September 24th. HC Wainwright decreased their target price on Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday. UBS Group cut their price target on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Wall Street Zen downgraded Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.50.

Harmony Biosciences Stock Up 2.8%

Harmony Biosciences stock opened at $34.31 on Friday. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.98 billion, a P/E ratio of 10.79, a P/E/G ratio of 0.43 and a beta of 0.85. The business has a fifty day moving average of $29.67 and a two-hundred day moving average of $32.97. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.93.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). The company had revenue of $239.46 million during the quarter, compared to analysts’ expectations of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.